Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | YAP1 | P46937 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460974 | 1.00 | BCL2 (0.56) | BCL2PTPN1CAPN1ATMPPARG | |
| SCHEMBL5353421 | 1.00 | BCL2 (0.56) | BCL2PTPN1CAPN1ATMPPARG | |
| SCHEMBL15565812 | 0.91 | RXRA (0.53) | BCL2PTPN1CAPN1PPARGHDAC8 | |
| SCHEMBL390555 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL7094 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL1094506 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL14423620 | 0.89 | PTPN1 (0.55) | BCL2PTPN1ATMPPARGYAP1 | |
| SCHEMBL16991080 | 0.88 | NPC1 (0.51) | BCL2PTPN1CAPN1ITGB3ITGA2B | |
| SCHEMBL16991078 | 0.88 | NPC1 (0.51) | BCL2PTPN1CAPN1ITGB3ITGA2B | |
| SCHEMBL15414385 | 0.88 | PTPN1 (0.57) | BCL2PTPN1ATMPPARGYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977371-A | Tandem asymmetric transformation process | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-12285491-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| US-5559140-A | VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0565631-B1 | ANTI-VIRAL COMPOUNDS | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| EP-0707564-A1 | DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1996002499-A1 | DIFLUOROSTATONE ANTIVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1995021186-A1 | MACROCYCLIC DIFLUOROSTATONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995001958-A1 | DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-19 | — | — | WO | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| EP-0565631-A1 | ANTI-VIRAL COMPOUNDS. | MERRELL DOW PHARMA (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992012123-A1 | ANTI-VIRAL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | BCL2 363/4885PTPN1 2381/4885CAPN1 1722/4885 |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | BCL2 785/4885PTPN1 3907/4885CAPN1 735/4885 |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | BCL2 1716/4885PTPN1 3946/4885CAPN1 3251/4885 |
| US-12285491-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | BCL2 785/4885PTPN1 3907/4885CAPN1 735/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | BCL2 1716/4885PTPN1 3946/4885CAPN1 3251/4885 |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | BCL2 785/4885PTPN1 3907/4885CAPN1 735/4885 |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | BCL2 1716/4885PTPN1 3946/4885CAPN1 3251/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | BCL2 972/4885PTPN1 1785/4885CAPN1 931/4885 |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | BCL2 785/4885PTPN1 3907/4885CAPN1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.